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The critical  differences between normal and activated macrophages  I have 
not been  completely defined.  Karnovsky et  al.  (1)  have suggested that  the 
metabolic  functions of macrophages differ  depending on  whether  they  are 
activated by  immunomodulaters such as  bacille  Calmette-Gudrin or pyran, 
stimulated (elicited) by inoculation with sterile inflammatory agents such as 
thioglycollate or glycogen, or are  normal  (unstimulated).  Macrophages har- 
vested  from  animals  with  chronic  intracellular  protezoal  (2)  or  bacterial 
infections (3) have been shown to spread quickly on glass surfaces and they 
contained  greater  numbers  of lysosomes,  mitochondria,  and  other  cellular 
inclusions than did normal macrophages (4). Moreover, immunologically acti- 
vated  macrophages also  exhibited enhanced spreading,  adherence,  motility, 
phagocytosis, pinocytosis, and glucose-l-carbon oxidation  (4). Several recent 
reports have indicated that activated and stimulated macrophages responded 
by increased secretion of lysozyme (5), plasminogen activator (6), collagenase 
(7), and the second component of complement (8). Similarly, carrier-mediated 
transport of 2-deoxy-v-glucose and L-leucine was increased in immunologically 
activated macrophages (9). While some of the metabolic differences between 
normal vs. stimulated or activated macrophages seem to be clear-cut, metabol- 
ically diferentiating the continuum from stimulation to activation has been 
difficult. Functionally, only activated and not elicited or normal macrophages 
have been shown to be cytotoxic and cytostatic to tumor cells (10, 11). 
Many of the characteristics associated with activation are clearly related to 
enhanced membrane activity (e.g., membrane ruffling, glucosamine incorpora- 
tion, pinocytosis, phagocytosis). In this report we describe an antiserum which 
detects  a  membrane  antigen  specifically  associated  with  Corynebacterium 
parvum  and pyran-activated macrophages but not detectable on glycogen, or 
thioglycollate-elicited or normal macrophages. This antiserum provides a sim- 
ple  reproducible  tool  for  differentiating  activated  macrophages  from  their 
normal or stimulated counterparts. 
Materials and Methods 
Animals.  Male and female C57B1/6, A/He,  DBA/2,  BALB/c, and BDF~  mice were obtained 
* Supported in part by grants IM112 and IN-105B from the American Cancer Society. 
In  this  manuscript,  the  term  "activated  macrophage"  is  reserved  for  that  population  of 
macrophages that exhibits cytostasis and cytotoxicity for neoplastic cells. 
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from  Jackson  Laboratories,  Bar  Harbor,  Maine,  Simonsen  Laboratories,  Gilroy,  Calif.,  or 
Charles River Breeding Laboratories, Wilmington, Mass. 
Reagents.  Pyran  (lot XA124-177,  Hercules Inc.,  Wilmington,  Del.), C. parvum  (Burroughs 
Wellcome Co.,  Research Triangle Park,  N.  C.),  glycogen  (type II from oyster,  Sigma G-8751, 
Sigma Chemical Co., St. Louis, Mo.), and thioglycollate (Brewer's thioglycollate, Difco Labora- 
tories, Detroit, Mich.) were used to induce peritoneal exudates as previously described (10, 11). 
Cell Preparation.  Peritoneal exudate cells (PEC) were obtained 4-7 days after i.p. inoculation 
of glycogen (0.5  ml/mouse of a  2.5%  solution),  thioglycollate  (1  ml/mouse of a  10%  solution), 
pyran (25 mg/kg), or C. parvum (17.5 mg/kg), by washing the peritoneal cavity twice with 4 ml of 
RPMI  1640. The PEC were collected by centrifugation at 500 g  for 10 rain,  washed twice with 
Hanks' balanced salt solution (HBSS), and resuspended in HBSS with 5% fetal calf serum (FCS) 
previously absorbed  with mouse spleen cells (AFCS). To obtain peritoneal macrophages  (PM), 
PEC were resuspended in RPMI-1640 with 20% FCS and distributed at 4 x  107 PEC per plate into 
Petri dishes  (100  ×  15 mm) and  incubated  at 37°C in 5% CO2 for 2 h.  Nonadherent  cells were 
washed off twice with RPMI-1640 without FCS, centrifuged at 500 g  for 10 min, and resuspended 
in HBSS with 5% AFCS. Adherent cells (PM) were removed from the plates by gently scraping 
with a rubber policeman. The cells were centrifuged, washed twice with HBSS, and resuspended 
in HBSS with 5% AFCS. Greater than 95% of the adherent cells phagocytosized latex particles 
and were esterase positive (12). Single cell suspensions of the thymus were prepared by teasing 
the tissue in RPMI-1640 and forcing it through a wire screen. Thymus cells were washed twice 
and resuspended in HBSS with 5% AFCS. 
The P388 leukemia was maintained in DBA/2 mice. Before using the P388 cells for absorptions, 
adherent  cells  were  removed  as  described  for  the  PEC.  The  macrophage  cell  line,  P388D1, 
originally obtained from Dr. H. S. Koren (Duke University, Durham,  N. C.) was maintained in 
spinner  flasks  in  Eagle's  Minimal  Essential  Medium  supplemented  with  20%  FCS,  2  mm 
glutamine, and containing 100 U  of penicillin and 100 ~g streptomycin at 37°C in 5% CO2. This 
cell line was originally isolated by Dawe and Potter  (13) from the P388 DBA/2 mouse leukemia 
and was recently characterized by Koren et al.  (14). 
Preparation  of Antiserum.  Heterologous  anti-macrophage  serum  (AMS)  was  prepared  by 
injecting rabbits  i.v. with P388D1  cells (2  x  107 to 7  x  l0  T cells per injection).  The particular 
antiserum described in this report was obtained from a rabbit 10 days after the eighth inoculation 
with  P388D1  over  a  1-yr  period.  The  Ig  from  a  33%  ammonium  sulfate  precipitate  of the 
antiserum  was  rendered  specific for macrophages  by repeated  absorptions  at 4°C  with DBA/2 
thymocytes and P388  leukemia cells depleted of contaminating adherent cells. Absorptions were 
carried  out  until  no  cytotoxicity  for  thymocytes  was  detected.  Additional  absorptions  were 
performed similarly as described in the text. 
Cytotoxicity Testing and Immunofluorescence.  Cytotoxicity testing was performed by a stan- 
dard Amos two-stage technique (15). Rabbit serum complement absorbed with mouse spleen and 
thymus cells and agarose was used. Indirect immunofluorescence was performed using fluorescein 
isothiocyanate-conjugated  goat  anti-rabbit  IgG  absorbed  with  P388D1  cells.  The  assay  was 
carried out at 4°C in HBSS with 5% AFCS and 0.1%  sodium azide. 
Results 
The AMS absorbed with thymus and P388  cells was cytotoxic for adherent 
PM from both C. parvum and glycogen-treated mice (Fig. 1). When macrophage- 
specific AMS was absorbed twice with 108 normal PEC per ml of antiserum, 
the cytotoxic activity against the glycogen-elicited macrophages was completely 
removed while the cytotoxic activity against the C. parvum-activated  macro- 
phages was unchanged. Absorption of AMS with P338D1 removed the cytotoxic 
activity against C. parvum-activated  macrophages.  In a  similar experiment, 
AMS absorbed with normal PEC was cytotoxic for pyran-activated macrophages 
but not for glycogen,  or thioglycollate-elicited  macrophages.  To  rule  out the 
possibility that we were identifying a  strain-specific antigen,  pyran-activated 
PEC from five strains of mice (C57B1/6,  DBA/2, A, BALB/c, BDF,) were tested A.  M.  KAPLAN  AND  T.  MOHANAKUMAR  BRIEF  DEFINITIVE  REPORT  1463 
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Fro.  1.  Cytotoxicity  of  anti-macrophage  serum  (AMS)  for  C.  parvum-activated  and 
glycogen-elicited peritoneal macrophages: Target C. parvum-activated  macrophages tested 
with AMS (A), AMS absorbed with normal PEC (&), or AMS absorbed with P388D1  (I). 
Target glycogen-elicited peritoneal macrophages tested with AMS (©),  or AMS absorbed 
with normal PEC (e). 
FIG.  2.  Quantitative absorption assay of anti-macrophage serum absorbed with varying 
numbers  of PEC  from pyran-treated  mice  (e),  glycogen-treated mice  (A),  or untreated 
normal mice (I). AMS absorbed with the specified number of cells/milliliter of AMS was 
tested  at  a  dilution  of 1:2  against  glycogen-elicited PEC,  pyran-activated  PEC,  normal 
PEC, or P388D1  cells. The target cell is shown on each panel. 
and all were found equally susceptible to the cytotoxic activity of AMS absorbed 
with  normal  C57B1/6  PEC.  Furthermore,  absorptions  with  pyran-activated 
PEC from the C57B1/6 strain removed the cytotoxic reactivity of AMS to all 
the cell preparations tested (data not presented). 
To further characterize the specificity of the antiserum, quantitative absorp- 
tions of AMS were done with normal PEC, pyran-activated PEC, or glycogen- 
elicited PEC; the absorbed antisera were then tested for cytotoxicity against 
normal PEC,  glycogen-elicited PEC,  pyran-activated PEC,  and P388D1  cells. 
Absorption of AMS with normal or glycogen-elicited PEC removed the cytotoxic 
activity to normal and glycogen-elicited macrophages but not to pyran-activated 
macrophages or P388D1  cells (Fig.  2).  About 50% of the cytotoxic activity to 
normal or elicited PEC was removed by absorption of AMS with 107 normal or 
glycogen-elicited cells/ml and all the reactivity was  abolished by absorption 
with 108 normal or glycogen-elicited cells/ml. In contrast,  absorption of AMS 
with normal or glycogen-elicited PEC caused no significant reduction in the 
cytotoxic activity to P388D1  cells or pyran-activated macrophages. In addition, 
increasing the cell concentration to 109 normal or glycogen-elicited cells/ml did 
not significantly reduce the AMS reactivity to pyran-activated macrophages or 
P388D1  cells. However, absorption of the AMS with pyran-activated PEC (10  s 
cells/ml) removed cytotoxic activity against pyran-activated macrophages and 
the P388D1  cell line as well as against normal and glycogen-elicited macro- 
phages  (Fig.  2).  Both AMS and AMS  absorbed with  normal PEC  were not 
cytotoxic to thymus cells or nonadherent PEC. 
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FIG.  3.  Immunofluorescent and phase-contrast micrographs of pyran-activated PEC and 
P388D1  cells.  Pyran-activated  PEC  (A)  and  P388D1  cells  (C)  were  stained  with  rabbit 
AMS absorbed with normal PEC and fluoresceine-labeled goat anti-rabbit IgG. B and D are 
phase-contrast  micrographs  of the  same  microscope fields  of pyran-activated  PEC  and 
P388D1  cells presented in panels A and C, respectively. 
rescence was performed using normal rabbit serum, AMS or AMS absorbed 
with normal PEC  as  primary sera,  goat  anti-rabbit  IgG  as  the fluorescent 
developing antiserum, and normal PM,  pyran-activated PM,  and P388D1 as 
target cells. Fig. 3A and 3C show the patchy fluorescence  that was characteristic 
of pyran-activated macrophages and P388D1 cells respectively. The results in 
this system corroborated the results obtained with the cytotoxic assay (Table 
I).  Specific AMS stained normal macrophages, P388D1 cells, and pyran-acti- 
vated macrophages while the AMS absorbed with normal PEC stained only the 
pyran-activated macrophage and P388D1 cells. 
Discussion 
The results of this report indicate that macrophages activated by pyran or C. 
parvum  which are known to have increased biochemical activity and to be 
cytotoxic for tumor cells  (10, 11)  also  have  a  new macrophage cell-surface 
antigen. This antigen is also present on the P388D1 macrophage cell which 
functions as an activated macrophage as evidenced by cytostatic and cytotoxic 
activity for tumor cells (L. G. Baird and A. M. Kaplan, unpublished observa- 
tions). In contrast, this new macrophage cell-surface antigen was not detected 
on normal macrophages or macrophages elicited by glycogen or thioglycollate, 
which are known to have increased biochemical activity but are not cytotoxic 
for  tumor  cells  (10, 11). Preliminary studies  with  four  bacterial  vaccines, A.  M.  KAPLAN  AND  T.  MOHANAKUMAR  BRIEF  DEFINITIVE  REPORT 
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Target cell  Anti-rnacrophage  serum  Anti-macrophage  serum 
Normal rabbit serum  absorbed with normal PEC 
%  % 
Normal PEC  18  29  95 
Pyran PEC  21  >99  >99 
P388D1  19  >99  >99 
* Immunofluorescent  activity  of normal rabbit serum, anti-macrophage  serum, and anti-macrophage 
serum  absorbed  with  normal  PEC  for normal  PEM,  pyran  PEM  (activated) and  the  P388DI 
macrophage cell  line. 
Propionibacterium acnes,  type I  (CN1634, Burroughs Wellcome, C. parvum), 
P. acnes, type II (VPI 6637), P. acnes, type III (VPI 0204), and P. granulosum 
(VPI 6500) have indicated that only two vaccines, P. acnes,  type I  (CN1634) 
and P. acnes, type II (VPI 6637), could induce: (a) regression of the MCA 2182 
fibrosarcoma when inoculated intralesionally, (b) splenomegaly, and (c) peri- 
toneal macrophages cytotoxic to tumor cells in vitro. The new antigen associated 
with activated macrophages was only detectable on macrophages activated by 
the two vaccines (CN1634 and VPI 6637) which induced functionally activated 
cells (Kaplan, Mohanakumar, and Cummins, unpublished observations). 
Absorption  studies  with  different cell  concentrations  suggested  that  the 
presence of this antigen was not merely a quantitative phenomena but may be 
a qualitative one. The presence of this antigen on PM macrophages induced by 
C. parvum  and pyran and on P388D1 cells suggested that the antigen is not 
due to  a  product of the inducing agent itself.  However, further studies  are 
needed to substantiate whether this antigen is a newly synthesized antigen or 
an expression of an antigen which may be present in extremely low levels or 
cryptic in normal and elicited macrophages. Moreover, these studies do not 
address the question of whether this  antigen is a  single or multiple entity. 
Studies on the kinetics of antigen appearance indicated that the antigen could 
be  detected  on  PEC  from  mice  1  day  after  inoculation  with  pyran,  was 
maintained for 25 days, and was no longer detectable at day 30  (unpublished 
observations).  At all  of these times when pyran-induced macrophages were 
tested  against  activated  macrophage-specific AMS,  100% of the  peritoneal 
macrophages was lysed by antiserum and complement. Yet we know that the 
capacity  of pyran-activated peritoneal  macrophages to  mediate  tumor  cell 
cytotoxicity or to inhibit lymphoproliferation is at a peak level from ---3 to 14 
days after i.p.  pyran  inoculation  (10, 11). The function of cells within the 
antigen-positive population may be related to the amount of antigen present on 
the macrophage surface or, alternatively, the antigen may be a differentiation 
antigen  which  is  a  marker for,  but  of itself insufficient to  modulate  the 
function of, the macrophages. The relationship of this antigen to the function 
of activated macrophages and  to  other macrophage membrane receptors is 
currently under investigation. 
Summary 
A macrophage cell-surface antigen associated with pyran and Corynebacte- 1466  A.  M.  KAPLAN  AND  T.  MOHANAKUMAR  BRIEF  DEFINITIVE  REPORT 
rium parvum-activated macrophages  and P388D1  cells but not detectable on 
normal or glycogen and thioglycollate-elicited murine macrophages has been 
described.  The antigen was demonstrated both by complement-mediated cyto- 
toxicity and immunofluorescence, using an appropriately absorbed rabbit anti- 
serum  to P388D1.  This antiserum should enable the characterization of acti- 
vated macrophage cell populations on an individual cell basis and should be a 
useful probe to study the interactions of macrophages with tumor cells and the 
relationship of activation to cell-surface changes. 
We  thank  Ms.  Louis  Kirk for  her  technical  assistance  and  Ms.  Rae  Spivey for  typing the 
manuscript. 
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